Incidence of thyroid hormone therapy in patients treated with sorafenib or sunitinib

26th ICPE - International Conference on Pharmacoepidemiology and Therapeutic Risk Assessment, 19. - 22. August 2010, Brighton, England, UK: Pharmacoepi and Drug Safety 2010 Vol. 19 Suppl. 1 p. S 259 (Abstract number 611).

Interessenskonflikte: RQ, AF, SF, KS, MS: This investigation of the DAPI - German Institute for Drug use Evaluation has been financially supported by Sanofi-Aventis Deutschland GmbH, Berlin, in the years 2008 and 2009. RQ: Results of this study have been presented at the 12th Annual European ISPOR-Congress in Paris (October 24 - 27, 2009), the 16th annual meeting of the Gesellschaft für Arzneimittelepidemiologie (GAA) e. V. in Berlin (November 19 - 20, 2009), and the 70th scientific sessions of the American Diabetes Association in Orlando (June 25 - 29, 2010). Registration fees and travel costs have been paid by Sanofi-Aventis Deutschland GmbH. MU, KL, WEM: None. FWD: Employee of Sanovi-Aventis Deutschland GmbH, Berlin.